COVID-19 Funding Opportunities

These are funding opportunities available to medical researchers specific to the Coronavirus Disease (COVID-19). This list of funding opportunities specific to COVID-19 is updated on a regular basis.

Organization/Foundation Funding Opportunity / Grant Title Activity Code(s)
Office of The Director, National Institutes of Health (OD)  ǀ (NHLBI)  ǀ (NIAID)
(NIAMS)  ǀ (NICHD)  ǀ (NIDA)
(NIMHD)  ǀ (FIC)
Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional) R61/R33
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional) R01
NIH National Cancer Institute (NCI)

NOT-CA-20-082

National Cancer Institute (NCI) Emergency Administrative Supplements for Research and Training Continuity of Postdoctoral Fellows during Coronavirus Disease 2019 (COVID-19) 333
TD Bank 2020 TD Ready Challenge Initiative
Deadline: August 13, 2020
Amount: Grants ranging from $260,000 to $745,000
Office of The Director, National Institutes of Health (ODǀ  (NHLBIǀ (NHGRIǀ  (NIAǀ  (NIAID)
(NIAMSǀ  (NICHDǀ  (NIDCDǀ (NIDCR)
(NIDDKǀ (NIEHS) ǀ (NINDSǀ (NIMHD)
(NCCIHǀ (NCATS) ǀ (ORIPǀ (NCI)NOT-OD-20-129
333
National Institute on Minority Health and Health Disparities (NIMHD) ǀ (NIA) ǀ (NICHD) (NIDCD) (NIDCR)  ǀ (NIDA) ǀ (NIEHS) ǀ (NIMH) ǀ (NINR) ǀ (NCCIH) ǀ (ODP) ǀ (OBSSR) ǀ (ORWH) (NEI) ǀ (NIAAA) ǀ (NIDDK) (NCATS) ǀ(SGMRO)

PAR-20-237

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional) R01
National Center for Complementary and Integrative Health (NCCIH)
Office of Research on Women’s Health (ORWH) NOT-AT-20-012
Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) & Coronavirus Disease 2019 (COVID-19) 333
NIH Office of Strategic Coordination (Common Fund)

RFA-RM-20-021

NIH Director’s Emergency Early Independence Awards (DP5 Clinical Trial Optional) DP5
NIH Office of Strategic Coordination (Common Fund)

RFA-RM-20-020

NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional) R01
National Institute of Allergy and Infectious Diseases (NIAID)

NOT-AI-20-051

Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
R01, R43/R44, R41/R42
National Institute of Dental and Craniofacial Research (NIDCR)

NOT-DE-20-023

Infrastructure Access for Research on Coronavirus Disease 2019 (COVID-19) Conducted in the National Dental Practice-Based Research Network X01
National Institute of Dental and Craniofacial Research (NIDCR)

Office of Research on Women’s Health (ORWH)

NOT-DE-20-022

Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR 333
National Institute of Neurological Disorders and Stroke (NINDS)

NOT-NS-20-051

 

 Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System 333
National Institute of Allergy and Infectious Diseases (NIAID)
  1. Emergency Awards: Rapid Investigation of SARS-CoV-2 and COVID-19 (R01 Clinical Trial Not Allowed) PAR-20-178
  2. Emergency Awards: Rapid Investigation of SARS-CoV-2 and COVID-19 (R21 Clinical Trial Not Allowed) PAR-20-177
R01, R21
National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Point-of-Care Technology Research Network (POCTRN)

 

NIBIB is urgently soliciting proposals and will provide up to $500 million across multiple projects to produce SARS-CoV-2 diagnostic tests. The Rapid Acceleration of Diagnostics (RADx) program will support all phases of product development from conceptualization and design to prototyping, performance evaluation, clinical validation, and manufacturing. Proposals will be accepted on a rolling basis starting April 29 and will be reviewed within a week of submission.
National Heart, Lung, and Blood Institute (NHLBI)


NOT-HL-20-782

Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials 333
U.S. Department of Energy (DOE) The DOE National Virtual Biotechnology Laboratory (NVBL) is a resource available opening up the DOE national laboratory user facilities and specialized instrumentation to academic researchers and industry to address COVID-19. The NVBL lists all relevant DOE capabilities, such as light and neutron sources, nanoscale science centers, sequencing and bio-characterization facilities, and high performance computer facilities to help respond to COVID-19.
Department of Defense (DOD)
Defense Advanced Research Projects Agency (DARPA)
Biological Technologies Office (BTO)
HR001120S0044
DARPA /BTO‘s research and investment portfolio includes combating pandemic disease, microbes as production platforms, human performance and warfighter readiness, innovative physiological interventions, and environmental and ecological exploration. DARPA will fund BTO to support on-going COVID-19 efforts and potentially to new ideas that address near-term COVID-19 challenges.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NOT-AA-20-011

Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA 333
Office of Behavioral and Social Sciences Research(OBSSR
(NHLBI)ǀ (NIA
(NIAAA)ǀ (NIDDK
(NIEHS)ǀ(NCCIH
(NCI)NOT-OD-20-097
Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences
For investigators with existing NIH grants NIH Office of Behavioral and Social Science Research has announced a notice of special interest for administrative supplements and urgent competitive revisions.
333
National Institute on Minority Health and Health Disparities (NIMHD)

NOT-MD-20-019

Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities 333
National Center for Advancing Translational Sciences (NCATS)

NOT-TR-20-017

Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus 333
National Institute of Mental Health (NIMH)

NOT-MH-20-047

Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus 333
National Center for Advancing Translational Sciences (NCATS)

NOT-TR-20-016

Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus 333
National Institute of Environmental Health Sciences (NIEHS)

NOT-ES-20-015

NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) 333, R21
National Heart, Lung, and Blood Institute (NHLBI)

NOT-HL-20-759

NHLBI Announces Availability of Frequently Asked Questions (FAQs) for NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
National Institute on Aging (NIA), and
National Institute of Mental Health (NIMH)NOT-AG-20-022
NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) 333
Department of Defense
Dept. of the Army — USAMRAA
Peer Reviewed Medical Research Program (PRMRP)
PRMRP open to Emerging Viral Diseases and Respiratory Health with a focus on COVID-19:

National Institute on Aging (NIA), and
National Institute of Mental Health (NIMH)
NOT-AG-20-022
NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) 333
National Science Foundation (NSF) (NSF)

 

NSF Rapid Response Research (RAPID) funding mechanism for non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.
National Institute of Allergy and Infectious Diseases (NIAID)

NOT-AI-20-040

Notice of Early Expiration of “Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019
National Institute of General Medical Sciences (NIGMS)

NOT-GM-20-025

Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19)
National Institute on Drug Abuse (NIDA)

NOT-DA-20-047

Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus 333
National Center for Advancing Translational Sciences (NCATS)

NOT-TR-20-011

Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need 333,U01, R21, U54
National Institute of General Medical Sciences (NIGMS)

NOT-GM-20-025

Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 333
National Center for Advancing Translational Sciences (NCATS)

NOT-TR-20-012

Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) UH2, U01, U34
HHS ǀ Office of Biomedical Advanced Research and Development Authority (BARDA) ǀ Broad Agency Announcement (BAA) BARDA expanded its standard broad agency announcement to accept proposals for advanced development of diagnostics, vaccines, therapeutics and other medical products for use in the current COVID-19 emergency response and future coronavirus outbreaks

For more federal and non-federal COVID-19 research opportunities click here.

BACK TO TOP↑